‘Revolutionary’ liquid sickle cell treatment has been unveiled
A new liquid formulation of hydroxycarbamide to treat sickle cell disease will “enable doctors to personalise doses in children".
List view / Grid view
A new liquid formulation of hydroxycarbamide to treat sickle cell disease will “enable doctors to personalise doses in children".
The UK healthcare agency has issued an alert for Perrigo ranitidine products, recalling and quarantining certain batches.
A new report has predicted that gene therapy development will pick up pace but a high price point continues to pose a challenge.
A study has found that 25 percent of drugs with one or more new molecular entities approved by the FDA come from publicly funded research.
The FDA has announced its support of a drug manufacturer rating system that would allow purchasers to identify which have the most reliable supply, in an effort to reduce shortages.
A new agreement will allow eligible cystic fibrosis patients in England to have access to CFTR modulators to treat the underlying cause of their disease.
Encapsulation technology, a simple and efficient technique to coat liquid medication in milliseconds, could improve drug delivery.
The FDA has released an additional NDMA testing method and has alerted the public to multiple voluntary recalls of ranitidine.
Speaker Pelosi’s bill to lower medicine prices in the US has passed through a House committee, ready for a full vote.
Farxiga, a treatment to reduce the risk of heart failure in patients with type 2 diabetes has been approved by the FDA.
A new drug delivery technology has been developed using nanotubes which can efficiently and precisely target lung cancer cells.
Research has found that up to 60 percent of results for medicines on search engines present potentially counterfeit pharmaceutical products.
Aducanumab, an Alzheimer's disease treatment, will be submitted as part of a Biologics License Application after meeting clinical trial primary endpoints.
A business selling unapproved products containing CBD has been sent a warning letter from the FDA and FTC for making unsubstantiated claims about their therapeutic properties.
The FDA has released a statement on their generic drug approvals in FY 2019, revealing a new record high breaking above last year.